News

2017 Year in Review

MaRS Innovation looks back at the year that was: a summary of the main events of the past 12 months, including creation of LAB150, collaboration with strategic partners and significant investment events into our portfolio companies. For the full report, please follow the link:  Year in Review 2017-18   Read more

Zucara raises US$3.9M Funding to advance drug for hypoglycemia prevention

Toronto and Vancouver, Canada: Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding from The Leona M. and Harry B. Helmsley Charitable Trust. As part of the agreement, Helmsley will provide the funding to support preclinical advancement of Zucara’s lead drug candidate. The partnership is structured as a program-related investment (PRI) in the form of a loan to Zucara. Zucara recently defined its lead drug candidate ... Read more

$800,000 MaRS Innovation–Pfizer Translational Research Fund

KIRKLAND, Quebec and TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- Pfizer Canada is proud to announce an $800,000 contribution to MaRS Innovation to support the vision and mission of MaRS Innovation by providing funding for new ideas or technologies in the health sciences including; therapeutics, diagnostic and treatment tools, manufacturing technologies, and technologies that enable health sciences research. The MaRS Innovation – Pfizer Translational Research Fund will be managed by MaRS Innovation and projects in the area of cardiovascular disease, inflammation, immunology, ... Read more

Zucara Therapeutics Inc. Receives Support from NCR-IRAP

VANCOUVER and TORONTO, Canada — January 8, 2018 - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has received support of up to $350,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition, The Centre for Drug Research and Development (CDRD) and MaRS Innovation have contributed follow on funding to the Company’s existing convertible note. Zucara recently defined its lead drug candidate, ZT-01, and ... Read more

LAB150 – A new paradigm in drug discovery

Click on link to read an article by Drs. Rafi Hofstein and Werner Lanthaler published in December 2017 in the online publication Global University Venturing: http://bit.ly/2Ba9vH2 Read more

QD Solar Secures Over $10M for Development of Solar Energy Technologies

TORONTO (February 13, 2017):  QD Solar, a Canadian technology company created by MaRS Innovation and the University of Toronto, announced today the closing of a C$2.5M Series A funding led by DSM Venturing, with matching investment participation from existing investors, MaRS innovation and KAUST Innovation Fund. The development of this technology is also supported by project funding that was announced in March 2016 from Sustainable Development Technology Canada (SDTC) through a C$2.5M grant, and through the generous support of the Ontario Research ... Read more

Important paper on Type 1 Diabetes and Exercise

New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers. Experts from JDRF, the leading global organization focused on type 1 diabetes (T1D) research, as part of an international team of 21 researchers and clinicians led by York UniversityProfessor Michael Riddell, published first-of-its-kind guidelines to help people with type 1 diabetes exercise safely. The report, “Exercise management in type 1 diabetes: a consensus statement,” published this week in The Lancet Diabetes & Endocrinology, offers guidelines on ... Read more

Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia

VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI). This unique deal brings together three organizations mandated with enabling the growth of Canada’s health sciences sector. Each partner brings its respective strengths to the table: capital, ... Read more

XOR Labs Closes $2.85 M in New Financing

XOR-Labs Toronto (XOR) a spin-oXOR-Labs Toronto (XOR) a spin-off from Toronto General Hospital at University Health Network today announced the closing of another financing through a private placement, led by lead investor Regenesis Limited Partnership, along with the participation of its existing investors, including Xenios AG and MaRS Innovation. The total raised in this round is CAN$2.85M. This is a solid vote of confidence and the second investment in XOR for Xenios which invested an additional CAN$2.6M in the company in ... Read more

ScarX announces approval for trial of first clinically-promising scar reduction cream

Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring. This announcement was covered in Yahoo Finance, The Canadian Business Journal, Global News Wire, and BioSpace. Applied immediately after surgical wound closure, SCX-001 reduces the amount of scar tissue that develops during the body’s natural healing process. The 24-subject Phase I clinical trial will be conducted at ... Read more
Page 1 of 3212345...102030...Last »